The effects of transdermal scopolamine and four dose levels of oral scopolamine (0.15, 0.3, 0.6, and 1.2 mg) upon psychological performance.
Four dose levels of oral scopolamine (0.15 mg, 0.3 mg, 0.6 mg, 1,2 mg), transdermal scopolamine, and placebo, were investigated for their effects upon a battery of psychological performance measures in normal subjects. Oral scopolamine produced significant linear dose-related decrements on tasks involving continuous attention, continuous performance, memory storage for new information, and on self-rated feelings of alertness and sociability. Transdermal scopolamine produced significant performance impairments on these same assessment measures. Resting heart rate levels were significantly reduced by all scopolamine conditions. Side effects (dry mouth, dizziness) were frequent following transdermal scopolamine and the higher oral dose conditions. The overall effects of the transdermal scopolamine patch were broadly equivalent to the effects of 0.8 mg oral scopolamine. This oral dose equivalence for transdermal scopolamine is higher than expected, and possible reasons for this are discussed.
D000284:Administration, Oral; D000287:Administration, Topical; D000328:Adult; D000339:Affect / Q000187:drug effects; D003071:Cognition / Q000187:drug effects; D005425:Flicker Fusion / Q000187:drug effects; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects; D008606:Mental Processes / Q000187:drug effects*; D011597:Psychomotor Performance / Q000187:drug effects; D011930:Reaction Time / Q000187:drug effects; D012601:Scopolamine / Q000008:administration & dosage / Q000494:pharmacology*; D014796:Visual Perception / Q000187:drug effects
D012601:Scopolamine